Legal & General Group Plc Has $318.05 Million Stake in Becton, Dickinson and Company $BDX

Key Points

• Legal & General increased its BDX position by 1.5%, adding 30,766 shares to own 2.10 million shares valued at approximately $318.05 million. Institutional investors collectively hold 86.97% of the company.
• Becton, Dickinson exceeded quarterly earnings and revenue expectations, reporting $3.23 in EPS and $4.98 billion in revenue, while revenue rose 5.4% year over year. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• The company declared a quarterly dividend of $1.05 per share, or $4.20 annualized, representing a 2.2% yield. Analysts’ average rating is “Hold,” with an average price target of $185.67.

Legal & General Group Plc raised its position in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,101,695 shares of the medical instruments supplier's stock after purchasing an additional 30,766 shares during the quarter. Legal & General Group Plc owned 0.76% of Becton, Dickinson and Company worth $318,050,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of BDX. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter worth about $25,000. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the 4th quarter valued at about $26,000. Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock valued at $27,000 after acquiring an additional 102 shares in the last quarter. Main Street Group LTD acquired a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc purchased a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $29,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

NYSE BDX opened at $189.87 on Wednesday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The company has a fifty day simple moving average of $163.37 and a 200 day simple moving average of $160.60. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company has a market cap of $52.32 billion, a P/E ratio of 57.19, a P/E/G ratio of 13.44 and a beta of 0.19.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the firm posted $3.68 EPS. The business's quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is currently 126.51%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BDX. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research report on Monday, May 11th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Becton, Dickinson and Company in a research note on Friday, August 7th. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday, July 28th. They set a "buy" rating and a $190.00 price objective for the company. Finally, Jefferies Financial Group restated a "buy" rating and issued a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $185.67.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm's stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the sale, the executive vice president owned 13,172 shares of the company's stock, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 11,704 shares of company stock worth $1,963,618 in the last 90 days. 0.40% of the stock is owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source